FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044207771> ?p ?o ?g. }

• W2044207771 endingPage "1813" @default.
• W2044207771 startingPage "1803" @default.
• W2044207771 abstract "Anticholinergic medications and onabotulinumtoxinA are used to treat urgency urinary incontinence, but data directly comparing the two types of therapy are needed.We performed a double-blind, double-placebo-controlled, randomized trial involving women with idiopathic urgency urinary incontinence who had five or more episodes of urgency urinary incontinence per 3-day period, as recorded in a diary. For a 6-month period, participants were randomly assigned to daily oral anticholinergic medication (solifenacin, 5 mg initially, with possible escalation to 10 mg and, if necessary, subsequent switch to trospium XR, 60 mg) plus one intradetrusor injection of saline or one intradetrusor injection of 100 U of onabotulinumtoxinA plus daily oral placebo. The primary outcome was the reduction from baseline in mean episodes of urgency urinary incontinence per day over the 6-month period, as recorded in 3-day diaries submitted monthly. Secondary outcomes included complete resolution of urgency urinary incontinence, quality of life, use of catheters, and adverse events.Of 249 women who underwent randomization, 247 were treated, and 241 had data available for the primary outcome analyses. The mean reduction in episodes of urgency urinary incontinence per day over the course of 6 months, from a baseline average of 5.0 per day, was 3.4 in the anticholinergic group and 3.3 in the onabotulinumtoxinA group (P=0.81). Complete resolution of urgency urinary incontinence was reported by 13% and 27% of the women, respectively (P=0.003). Quality of life improved in both groups, without significant between-group differences. The anticholinergic group had a higher rate of dry mouth (46% vs. 31%, P=0.02) but lower rates of catheter use at 2 months (0% vs. 5%, P=0.01) and urinary tract infections (13% vs. 33%, P<0.001).Oral anticholinergic therapy and onabotulinumtoxinA by injection were associated with similar reductions in the frequency of daily episodes of urgency urinary incontinence. The group receiving onabotulinumtoxinA was less likely to have dry mouth and more likely to have complete resolution of urgency urinary incontinence but had higher rates of transient urinary retention and urinary tract infections. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institutes of Health Office of Research on Women's Health; ClinicalTrials.gov number, NCT01166438.)." @default.
• W2044207771 created "2016-06-24" @default.
• W2044207771 creator A5019808095 @default.
• W2044207771 creator A5020587336 @default.
• W2044207771 creator A5022647956 @default.
• W2044207771 creator A5022693247 @default.
• W2044207771 creator A5025942222 @default.
• W2044207771 creator A5035024370 @default.
• W2044207771 creator A5040962057 @default.
• W2044207771 creator A5042545493 @default.
• W2044207771 creator A5042593746 @default.
• W2044207771 creator A5044844791 @default.
• W2044207771 creator A5065080439 @default.
• W2044207771 creator A5065864241 @default.
• W2044207771 creator A5073583281 @default.
• W2044207771 creator A5080840422 @default.
• W2044207771 date "2012-11-08" @default.
• W2044207771 modified "2023-10-04" @default.
• W2044207771 title "Anticholinergic Therapy vs. OnabotulinumtoxinA for Urgency Urinary Incontinence" @default.
• W2044207771 cites W1539553781 @default.
• W2044207771 cites W1987249698 @default.
• W2044207771 cites W1989155778 @default.
• W2044207771 cites W1993057480 @default.
• W2044207771 cites W2014075072 @default.
• W2044207771 cites W2042153553 @default.
• W2044207771 cites W2043328831 @default.
• W2044207771 cites W2076795362 @default.
• W2044207771 cites W2077126096 @default.
• W2044207771 cites W2087487100 @default.
• W2044207771 cites W2094952568 @default.
• W2044207771 cites W2120337742 @default.
• W2044207771 cites W2131173377 @default.
• W2044207771 cites W2135162196 @default.
• W2044207771 cites W2140362209 @default.
• W2044207771 cites W2141005094 @default.
• W2044207771 cites W2157993246 @default.
• W2044207771 doi "https://doi.org/10.1056/nejmoa1208872" @default.
• W2044207771 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3543828" @default.
• W2044207771 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23036134" @default.
• W2044207771 hasPublicationYear "2012" @default.
• W2044207771 type Work @default.
• W2044207771 sameAs 2044207771 @default.
• W2044207771 citedByCount "176" @default.
• W2044207771 countsByYear W20442077712013 @default.
• W2044207771 countsByYear W20442077712014 @default.
• W2044207771 countsByYear W20442077712015 @default.
• W2044207771 countsByYear W20442077712016 @default.
• W2044207771 countsByYear W20442077712017 @default.
• W2044207771 countsByYear W20442077712018 @default.
• W2044207771 countsByYear W20442077712019 @default.
• W2044207771 countsByYear W20442077712020 @default.
• W2044207771 countsByYear W20442077712021 @default.
• W2044207771 countsByYear W20442077712022 @default.
• W2044207771 countsByYear W20442077712023 @default.
• W2044207771 crossrefType "journal-article" @default.
• W2044207771 hasAuthorship W2044207771A5019808095 @default.
• W2044207771 hasAuthorship W2044207771A5020587336 @default.
• W2044207771 hasAuthorship W2044207771A5022647956 @default.
• W2044207771 hasAuthorship W2044207771A5022693247 @default.
• W2044207771 hasAuthorship W2044207771A5025942222 @default.
• W2044207771 hasAuthorship W2044207771A5035024370 @default.
• W2044207771 hasAuthorship W2044207771A5040962057 @default.
• W2044207771 hasAuthorship W2044207771A5042545493 @default.
• W2044207771 hasAuthorship W2044207771A5042593746 @default.
• W2044207771 hasAuthorship W2044207771A5044844791 @default.
• W2044207771 hasAuthorship W2044207771A5065080439 @default.
• W2044207771 hasAuthorship W2044207771A5065864241 @default.
• W2044207771 hasAuthorship W2044207771A5073583281 @default.
• W2044207771 hasAuthorship W2044207771A5080840422 @default.
• W2044207771 hasBestOaLocation W20442077711 @default.
• W2044207771 hasConcept C126322002 @default.
• W2044207771 hasConcept C126894567 @default.
• W2044207771 hasConcept C142724271 @default.
• W2044207771 hasConcept C159110408 @default.
• W2044207771 hasConcept C168563851 @default.
• W2044207771 hasConcept C197934379 @default.
• W2044207771 hasConcept C204243189 @default.
• W2044207771 hasConcept C204787440 @default.
• W2044207771 hasConcept C27081682 @default.
• W2044207771 hasConcept C2777844464 @default.
• W2044207771 hasConcept C2777912814 @default.
• W2044207771 hasConcept C2778531004 @default.
• W2044207771 hasConcept C2778689640 @default.
• W2044207771 hasConcept C2778941218 @default.
• W2044207771 hasConcept C2779502394 @default.
• W2044207771 hasConcept C2779951463 @default.
• W2044207771 hasConcept C42219234 @default.
• W2044207771 hasConcept C71924100 @default.
• W2044207771 hasConcept C77411442 @default.
• W2044207771 hasConceptScore W2044207771C126322002 @default.
• W2044207771 hasConceptScore W2044207771C126894567 @default.
• W2044207771 hasConceptScore W2044207771C142724271 @default.
• W2044207771 hasConceptScore W2044207771C159110408 @default.
• W2044207771 hasConceptScore W2044207771C168563851 @default.
• W2044207771 hasConceptScore W2044207771C197934379 @default.
• W2044207771 hasConceptScore W2044207771C204243189 @default.
• W2044207771 hasConceptScore W2044207771C204787440 @default.
• W2044207771 hasConceptScore W2044207771C27081682 @default.

• next